15 completed, 1 terminated. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 15, Terminated 1 |
Follow Acellular Pertussis: new trials by email Literature Review of Acellular Pertussis trials Research Report on Acellular Pertussis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Infanrix hexa - Diphtheria, Hepatitis B | Phase 4 | Completed | GlaxoSmithKline | 551 | 2016-09-19 | 2020-01-14 |
| Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Infanrix hexa, Prevnar13 - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 601 | 2016-01-22 | 2019-07-09 |
| Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Boostrix TM (new syringe presentation), Boostrix TM (previous syringe presentation) - Diphtheria, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 671 | 2011-07-01 | 2018-08-10 |
| Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Blood Sampling - Tetanus, Poliomyelitis | Phase 4 | Completed | GlaxoSmithKline | 58 | 2011-05-30 | 2021-01-19 |
| Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults BoostrixTM Polio - Acellular Pertussis, Poliomyelitis | Phase 4 | Completed | GlaxoSmithKline | 212 | 2011-04-01 | 2018-06-06 |
| Evaluation of Boostrix™10 Years After Previous Booster Vaccination Boostrix™, Boostrix™-US formulation - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 180 | 2010-06-15 | 2018-08-20 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Infanrix™ hexa - Hepatitis B, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 224 | 2008-09-23 | 2019-11-27 |
| Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Infanrix™ penta, Infanrix™ hexa - Poliomyelitis, Acellular Pertussis | Phase 4 | Completed | GlaxoSmithKline | 283 | 2008-02-14 | 2018-06-06 |
| Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Boostrix-Polio - Poliomyelitis, Diphtheria | Phase 4 | Completed | GlaxoSmithKline | 415 | 2008-02-01 | 2018-06-06 |
| Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Boostrix TM - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 82 | 2008-01-01 | 2018-06-06 |
| Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 Boostrix™ - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 203 | 2007-11-05 | 2020-01-13 |
| US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Boostrix®, Menactra™ - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 1344 | 2006-01-25 | 2018-08-17 |
| Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants GSK Biologicals' combined DTPa-IPV/Hib vaccine - Diphtheria, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 2590 | 2004-11-02 | 2020-01-02 |
| Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA), DTPa-HBV-IPV-Hib vaccine (HEXAVAC™) - Hepatitis B, Poliomyelitis | Phase 4 | Completed | GlaxoSmithKline | 494 | 2003-10-01 | 2016-08-05 |
| Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines. INFANRIX, BOOSTRIX, HAVRIX - Acellular Pertussis, Tetanus | Phase 4 | Terminated | GlaxoSmithKline | 720 | 2003-05-01 | 2016-09-07 |
| Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Boostrix™ (dTpa), GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM), Ditanrix™ Adult, TedivaxTM (Td) - Acellular Pertussis, Tetanus | Phase 4 | Completed | GlaxoSmithKline | 460 | 2003-04-01 | 2016-09-15 |
Diphtheria (16) · Tetanus (16) · Poliomyelitis (9) · Haemophilus Infections (5) · Hepatitis B (5) · Whooping Cough (4)
Actinomycetales Infections (16) · Bacterial Infections (16) · Bacterial Infections and Mycoses (16) · Clostridium Infections (16) · Corynebacterium Infections (16) · Gram-Positive Bacterial Infections (16) · Infections (16) · Central Nervous System Diseases (9) · Central Nervous System Infections (9) · Enterovirus Infections (9) · Myelitis (9) · Nervous System Diseases (9) · Neuroinflammatory Diseases (9) · Neuromuscular Diseases (9) · Picornaviridae Infections (9)
Boostrix (5) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (2) · Blood Specimen Collection (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Hepatitis A Vaccines (1) · Hexavac (1) · Meningococcal Vaccines (1) · PEDIARIX (1) · Pentetic Acid (1) · Poliovirus Vaccine, Inactivated (1) · Tetanus Toxoid (1)
GlaxoSmithKline (16)
Australia (4) · Finland (4) · Canada (3) · Italy (3) · Spain (3) · Belgium (2) · Czechia (2) · Germany (2) · Sweden (2) · Chile (1) · France (1) · Mexico (1) · Netherlands (1) · Norway (1) · Russia (1)
PMID 20448468, PMID 21134450, PMID 25613716, PMID 25882172, PMID 26075317, PMID 31776027, PMID 33612341
2014 (2), 2015 (1)